Elevance Health, Inc. (ELV) stock price, news and key stats

Price

Last trade as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$417.15

Open

$418.51

Day range

$411.86 – $420.72

Volume

47.9K

52-week range

$274.84 – $436.24

Market cap

$89.5B

Forward P/E

14.0

Dividend yield

165.00%

Beta

0.70

Avg. volume

1.3M

Analyst target

$450.05

Next earnings

Oct 21, 2026

About Elevance Health, Inc.

From the company's latest annual report (Form 10-K).

Latest ELV news

• Medicare Advantage patients who get diagnosed with Alzheimer’s or other serious diseases are ditching their plans — and it can cost them
  MarketWatch · Sep 5, 2026

  Medicare Advantage patients diagnosed with Alzheimer’s or other serious illnesses are increasingly opting to switch to traditional Medicare, a move that can lead to significant financial and logistical challenges. This trend is partly driven by the rising medical costs associated with complex conditions, which are often not adequately covered by Medicare Advantage plans. As a result, patients may find themselves facing higher out-of-pocket expenses and limited access to necessary care. Elevance Health has reported that the rising costs of medical care under Medicare Advantage plans are prompting insurers to implement stricter authorization processes. This has led some hospitals to reconsider their contracts with Medicare Advantage providers, potentially leaving patients without in-network options for critical services. The shift not only complicates care for patients but also raises concerns about the overall sustainability of Medicare Advantage plans as they grapple with increasing demand and costs. Market implications of this trend are significant. As more patients transition to traditional Medicare, insurers may need to reassess their pricing models and coverage options to remain competitive. Additionally, hospitals and healthcare providers could face disruptions in patient flow and revenue if they continue to withdraw from Medicare Advantage contracts. This evolving landscape underscores the need for both patients and providers to navigate the complexities of Medicare options carefully, particularly as the population ages and the prevalence of chronic diseases rises.

• Elevance Health (ELV): Bridging the Gap between Care and Coverage
  Yahoo Finance · Sep 1, 2026

  Elevance Health (ELV) experienced a notable rally of 6.7% following the announcement of a 2.48% increase in Medicare Advantage rates. While this uptick is a positive signal for the company, it remains overshadowed by concerns regarding medical inflation and the broader economic landscape. Analysts have pointed out that the rate increase does not fully align with rising healthcare costs, which could impact Elevance's profitability in the long run. Despite the short-term gains, Elevance's guidance for 2026 indicates potential challenges ahead, including a forecasted decline in membership, revenues, and operating income. This outlook raises questions about the sustainability of the company's growth trajectory. Investors are weighing these factors against the bullish sentiments expressed in recent analyses, which suggest that Elevance could still be a compelling investment opportunity if it successfully bridges the gap between care and coverage in a competitive market. As the healthcare sector continues to evolve, Elevance's ability to adapt to regulatory changes and manage operational efficiencies will be critical. Market participants will be closely monitoring the company's performance in the coming quarters, particularly in light of the Medicare Advantage rate adjustments and the overall economic environment, which could influence investor sentiment and stock performance.

• Vulcan Value Partners buys Equifax, exits Sodexo and Partners Group Holding in Q2
  Seeking Alpha · Jul 25, 2026

  Vulcan Value Partners has made notable adjustments to its investment portfolio in the second quarter of 2026, initiating a new position in Equifax, Inc. (EFX) while exiting its stakes in Sodexo SA (SDXAY) and Partners Group Holding AG (PGPHF). This strategic shift reflects the firm's ongoing commitment to optimizing its Large Cap strategy, which has recently shown strong performance, particularly driven by significant contributions from UnitedHealth Group Inc. and Elevance Health Inc. The decision to invest in Equifax comes at a time when the company is focusing on enhancing its data analytics capabilities and expanding its services in the credit reporting sector. This move could position Vulcan Value Partners to benefit from potential growth in Equifax's revenue streams as the economy continues to recover. Conversely, the divestments from Sodexo and Partners Group may indicate a reevaluation of sectors that Vulcan believes are less favorable for future growth, particularly in light of changing market dynamics and consumer behavior. Market analysts will be watching closely to see how these changes impact Vulcan's overall portfolio performance in the coming quarters. The firm’s ability to pivot effectively in response to market trends could serve as a bellwether for investment strategies in the large-cap space, particularly as investors seek to navigate the complexities of a post-pandemic economy.

• Sequoia Strategy trims Sunbelt, Elevance; exits Liberty Broadband
  Seeking Alpha · Jul 20, 2026

  Sequoia Strategy has made significant adjustments to its portfolio, trimming investments in Sunbelt Rentals and Elevance Health while completely exiting its holdings in Liberty Broadband and Credit Acceptance Corp. These moves were executed with a focus on tax efficiency, particularly in light of upcoming financial reporting periods. The strategy reflects a shift in focus as Sequoia reallocates capital towards new opportunities, including increased stakes in Bio-Techne and SAP, alongside a yet-to-be-disclosed new position that will be detailed in their year-end letter. The decision to exit Liberty Broadband is particularly noteworthy, given the stock's previous underperformance despite rising earnings per share. This divestment could signal a broader trend among investors reassessing growth prospects in the telecommunications sector, especially as market conditions evolve. The trimming of Sunbelt Rentals and Elevance Health investments may indicate a strategic pivot away from sectors that have shown volatility, particularly in the wake of pandemic-related fluctuations in healthcare utilization. As Sequoia Strategy reallocates its investments, market watchers will be keen to see how these changes impact overall portfolio performance and whether the new positions will yield favorable returns in the current economic climate. The adjustments may also reflect a cautious approach amid ongoing uncertainties in various sectors, prompting investors to seek stability and growth in more resilient companies.

• S&P 500 Futures Climb in Premarket Trading; Pentair, Elevance Health Lag
  Futures Trading · Jul 15, 2026

  S&P 500 futures rose in premarket trading, indicating a positive start for the index as investors anticipate potential gains in the broader market. This upward movement suggests a continuation of the bullish sentiment that has characterized recent trading sessions, driven by optimism surrounding economic recovery and corporate earnings. The futures market reflects a growing confidence among traders, with many looking for signs of resilience in key sectors. However, not all stocks are participating in the rally. Pentair and Elevance Health are lagging behind, indicating specific challenges within these companies that may be affecting investor sentiment. The underperformance of these stocks could signal sector-specific issues or broader market concerns that investors should monitor closely. As the trading day unfolds, market participants will be keen to assess how these developments impact overall market dynamics and whether the gains in S&P 500 futures translate into sustained momentum for the index.

• Molina, Centene, and Oscar are down after Elevance Health’s Q2 report
  Seeking Alpha · Jul 15, 2026

  Elevance Health's disappointing Q2 2026 earnings report has sent shockwaves through the healthcare insurance sector, leading to significant declines in the stock prices of its peers, including Molina Healthcare and Centene Corporation. Elevance's stock plummeted approximately 12% following its earnings release, while Molina's shares fell around 8%. The downturn reflects broader concerns about rising costs and operational challenges within the Medicaid and Affordable Care Act segments, which have been exacerbated by recent legislative changes. Centene's decision to withdraw its 2025 outlook has raised alarms among investors, as the company grapples with escalating expenses in its Medicaid division and deteriorating performance in its ACA plans. Molina, on the other hand, pre-announced its Q2 results, lowering expectations due to medical cost pressures affecting multiple business lines. This combination of negative news has created a ripple effect across the sector, impacting not only Molina and Centene but also other major players like Cigna and Humana. The recent volatility in Medicaid stocks underscores the fragility of the healthcare insurance market, particularly in light of legislative shifts that have introduced uncertainty. Investors are now closely monitoring how these companies will navigate rising costs and regulatory challenges, as further declines could prompt a reevaluation of the sector's growth prospects. As the market digests these developments, the focus will likely remain on how these firms adapt to the evolving landscape and manage their financial outlooks moving forward.

• Elevance Health (ELV) Fell Amid Healthcare Sector Downturn
  Yahoo Finance · Jun 29, 2026

  Elevance Health (ELV) experienced a notable decline in its stock price, falling 12% amid a broader downturn in the healthcare sector. This drop comes on the heels of a 3.41% decrease earlier in March, attributed to sanctions imposed by the Centers for Medicare & Medicaid Services (CMS) for alleged noncompliance in data submissions over a seven-year period. These sanctions have raised concerns about potential revenue losses from Medicare Advantage plans, further exacerbated by an ongoing shareholder probe and a securities investigation that have shaken investor confidence. Despite these challenges, analysts suggest that Elevance Health may ultimately benefit from increased market share and enhanced earnings power as it navigates this turbulent period. The company's fourth-quarter results for 2025 were in line with expectations, indicating disciplined management in a complex environment. As Elevance focuses on improving affordability and accessibility in healthcare for its members, the current stock decline may present a potential buying opportunity for investors willing to look beyond short-term volatility. However, the ongoing regulatory pressures and governance risks will require close monitoring as the company seeks to stabilize its operations and restore investor trust.

• It’s not just UnitedHealth, its Medicare peers are also rallying
  Seeking Alpha · Jun 5, 2026

  UnitedHealth Group has seen a notable rally in its stock, reflecting broader optimism in the Medicare Advantage (MA) market, where its peers are also experiencing gains. This surge comes amid significant industry shifts, including Cigna's recent $3.7 billion sale of its MA business to Health Care Service Corporation. According to Chartis, over 80% of the 1.7 million new MA beneficiaries have opted for for-profit plans, which include major players like UnitedHealthcare, Humana, and Aetna. The focus on at-home care initiatives among these companies is expected to play a crucial role in shaping the future of the $500 billion Medicare Advantage program. Despite the positive momentum, the sector faces challenges, particularly rising medical costs that have prompted companies like Centene Corporation and Elevance Health to revise their financial outlooks for 2025. Centene, for instance, has drastically lowered its adjusted earnings per share forecast from $7.25 to $1.75, signaling potential headwinds for profitability in the near term. UnitedHealth, trading just below its five-year average price-to-earnings ratio, is leveraging its integrated business model to navigate these challenges, positioning itself not just for survival but for growth in a competitive landscape. The performance of these companies in addressing cost pressures will be critical in determining their market trajectories moving forward.

• Elevance again avoids Medicare Advantage sanctions, but threat remains
  Geopolitics · Jun 1, 2026

  Elevance Health has successfully averted immediate sanctions from the Centers for Medicare & Medicaid Services (CMS) regarding its Medicare Advantage plans, receiving an extension until May 30, 2026, to rectify ongoing issues related to risk adjustment data reporting. This reprieve comes after the company demonstrated progress in addressing the faulty data submissions that had previously raised concerns among regulators. However, CMS has emphasized that further improvements are necessary to avoid future penalties, which could include an enrollment freeze. The extension allows Elevance to continue its operations without immediate disruption, but the looming threat of sanctions still casts a shadow over the company. The potential for enrollment freezes could impact Elevance's market position and financial performance, particularly as the Medicare Advantage segment is a significant revenue driver for the company. Investors and stakeholders will be closely monitoring Elevance's compliance efforts and the effectiveness of its data management systems to ensure that the company can maintain its standing in the competitive healthcare market.

• Elevra Lithium to divest Ewoyaa project stake to Huayou Cobalt for $71M
  Seeking Alpha · May 11, 2026

  Elevra Lithium Limited (ASX:ELV) has agreed to sell its entire interest in the Ewoyaa Lithium Project in Ghana to Zhejiang Huayou Cobalt Co., Ltd. for a gross cash consideration of approximately US$71 million. The binding Scheme Implementation Deed, announced to the ASX, covers all of Elevra’s rights and interests in the project, including its offtake rights, and is expected to close in the third quarter of 2026. The transaction is one of the largest recent moves in the African lithium market and signals a continued trend of consolidation among lithium developers on the continent. For Elevra, the proceeds will strengthen its balance sheet, reduce debt, and free up capital to pursue other growth opportunities or to streamline its portfolio. Huayou, a major Chinese cobalt producer, is expanding its lithium footprint to secure a more integrated supply chain for battery materials. The deal may also influence investor sentiment toward ASX‑listed lithium companies, as it demonstrates that Chinese firms are willing to invest heavily in African lithium assets, potentially raising valuations for comparable projects and encouraging further capital inflows into the sector. The sale underscores a broader shift in the global lithium supply chain, with Chinese and other foreign investors increasingly acquiring stakes in African lithium projects to hedge against supply disruptions and to secure access to high‑grade resources. While the transaction may boost confidence in the viability of Ghanaian lithium projects, it also raises questions about resource ownership and the long‑term impact on local economies. Market analysts will likely reassess growth forecasts for both Elevra and Huayou, and the ASX lithium index may experience short‑term volatility as investors digest the implications of this consolidation wave.

All 12 articles in the app →

Earnings history

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen